• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Commentary: Shared decision making for weight-lowering medications in China.

作者信息

Jia Qingyi, Li Sheyu

机构信息

Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Chinese Evidence-Based Medicine Center, Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

出版信息

Clin Transl Med. 2024 Nov;14(11):e70065. doi: 10.1002/ctm2.70065.

DOI:10.1002/ctm2.70065
PMID:39448555
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11502301/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41b7/11502301/f6f51d57c36b/CTM2-14-e70065-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41b7/11502301/f6f51d57c36b/CTM2-14-e70065-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41b7/11502301/f6f51d57c36b/CTM2-14-e70065-g001.jpg

相似文献

1
Commentary: Shared decision making for weight-lowering medications in China.评论：中国减肥药物的共同决策
Clin Transl Med. 2024 Nov;14(11):e70065. doi: 10.1002/ctm2.70065.
2
A resource guide to understanding cerebral palsy: Commentary on collaboration to support health literacy and shared decision making.了解脑瘫的资源指南：关于协作以支持健康素养和共同决策的评论。
J Pediatr Rehabil Med. 2021;14(2):173-182. doi: 10.3233/PRM-210026.
3
Assessing patient information needs for new antidiabetic medications to inform shared decision-making: A best-worst scaling experiment in China.评估患者对新型抗糖尿病药物的信息需求，以促进共同决策：在中国开展的最佳最差标度实验。
Health Expect. 2024 Jun;27(3):e14059. doi: 10.1111/hex.14059.
4
Exploring shared decision-making needs in lung cancer screening among high-risk groups and health care providers in China: a qualitative study.探索中国肺癌筛查高危人群和医疗服务提供者的共同决策需求：一项定性研究。
BMC Cancer. 2024 May 21;24(1):613. doi: 10.1186/s12885-024-12360-0.
5
Effects of a smartphone application named "Shared Decision Making Assistant" for informed patients with primary liver cancer in decision-making in China: a quasi-experimental study.中文译文：在中国，一款名为“共享决策助手”的智能手机应用程序对原发性肝癌知情患者决策的影响：一项准实验研究。
BMC Med Inform Decis Mak. 2022 May 31;22(1):145. doi: 10.1186/s12911-022-01883-w.
6
Shared decision-making and the lessons learned about decision regret in cancer patients.共享决策与癌症患者决策后悔的经验教训。
Support Care Cancer. 2022 Jun;30(6):4587-4590. doi: 10.1007/s00520-021-06725-5. Epub 2022 Jan 15.
7
'I think this medicine actually killed my wife': patient and family perspectives on shared decision-making to optimize medications and safety.“我认为这种药实际上害死了我的妻子”：患者及家属对优化用药与安全的共同决策的看法
Ther Adv Drug Saf. 2019 Apr 5;10:2042098619838796. doi: 10.1177/2042098619838796. eCollection 2019.
8
Patient decisional needs when considering treatment intensification for type 2 diabetes: A qualitative study in China.患者在考虑 2 型糖尿病强化治疗时的决策需求：中国的一项定性研究。
Diabetes Res Clin Pract. 2020 Dec;170:108471. doi: 10.1016/j.diabres.2020.108471. Epub 2020 Sep 28.
9
Primum Non Nocere: is shared decision-making the answer?“治人者必先自治，责人者必先自责，成人者必先自成。”：这是共享决策的答案吗？
Perioper Med (Lond). 2016 Jun 16;5:16. doi: 10.1186/s13741-016-0042-3. eCollection 2016.
10
Call for shared decision making in China: Challenges and opportunities.呼吁在中国进行共同决策：挑战与机遇。
Z Evid Fortbild Qual Gesundhwes. 2017 Jun;123-124:32-35. doi: 10.1016/j.zefq.2017.05.004. Epub 2017 May 19.

本文引用的文献

1
Adiposity in Chinese people with type 1 diabetes.1型糖尿病中国患者的肥胖问题。
World J Diabetes. 2024 Jul 15;15(7):1404-1408. doi: 10.4239/wjd.v15.i7.1404.
2
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.成人超重和肥胖的药物治疗：随机对照试验的系统评价和网络荟萃分析。
Lancet. 2024 Apr 6;403(10434):e21-e31. doi: 10.1016/S0140-6736(24)00351-9.
3
Sex-specific associations between skeletal muscle mass and incident diabetes: A population-based cohort study.
骨骼肌质量与新发糖尿病的性别特异性关联：一项基于人群的队列研究。
Diabetes Obes Metab. 2024 Mar;26(3):820-828. doi: 10.1111/dom.15373. Epub 2023 Nov 23.
4
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
5
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.药物治疗 2 型糖尿病的获益与危害：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2023 Apr 6;381:e074068. doi: 10.1136/bmj-2022-074068.
6
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics.肥胖症治疗的新前沿：基于胰高血糖素样肽-1和新生营养刺激激素的疗法
Annu Rev Med. 2023 Jan 27;74:125-139. doi: 10.1146/annurev-med-043021-014919.
7
Obesity pandemic in China: epidemiology, burden, challenges, and opportunities.中国的肥胖流行：流行病学、负担、挑战与机遇。
Chin Med J (Engl). 2022 Jun 5;135(11):1328-1330. doi: 10.1097/CM9.0000000000002189.
8
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.停用司美格鲁肽后的体重反弹和心脏代谢影响：STEP 1 试验延伸。
Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19.
9
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.